



G A O

Accountability * Integrity * Reliability

**United States Government Accountability Office
Washington, DC 20548**

Resp

*Archivi
cc: Sopko
Kyle
P. Jung*

January 24, 2008

The Honorable John D. Dingell
Chairman, Committee on Energy and Commerce
House of Representatives

Dear Mr. Chairman:

We received your letter dated January 16, 2008, jointly signed by Chairman Bart T. Stupak, Subcommittee on Oversight and Investigations, requesting that the Government Accountability Office update its report "NONPRESCRIPTION DRUGS: Value of a Pharmacist-Controlled Class Has Yet to be Demonstrated."

GAO accepts your request as work that is within the scope of its authority. To fully respond to your request, GAO plans to initiate work on this project in about two months when it is expected that staff with the required skills will be available. Your request has been assigned to Dr. Marjorie Kanof, Managing Director, Health Care. Dr. Kanof or a member of her team will contact Mr. Paul Jung to discuss the request and options for helping you meet your needs. As applicable, we will also be in contact with the cognizant Inspector General's office to ensure that we are not duplicating efforts. If an issue arises during this coordination, we will consult with you regarding its resolution.

If you have any questions, please contact Dr. Kanof at 202-512-5055 or Ms. Rosa Harris, Assistant Director for Congressional Relations, on my staff at 202-512-9492.

Sincerely yours,

Gloria L. Jarmon
Managing Director for
Congressional Relations

Ref: CCAR 08-0356